Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Oct;92(10):909-15.
doi: 10.1136/adc.2006.111500.

Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines

David Pace  1 , Andrew J Pollard
Affiliations
Review

Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines

David Pace et al. Arch Dis Child. 2007 Oct.

Abstract

Serogroup C meningococcal conjugate vaccines, first launched in the UK in 1999, have been used successfully in Australia, Canada and several other European countries. Combination conjugate vaccines, containing more than one meningococcal polysaccharide, have been developed to broaden protection against the disease. A tetravalent meningococcal A, C, Y and W-135 conjugate vaccine was licensed for use in 11-55 year old adolescents and adults in the US in January 2005, and subsequently also in 2-11 year old children in Canada in May 2006. This article discusses the different glycoconjugate meningococcal vaccines which have been developed and the potential for their use to control disease caused by serogroups A, C, Y and W-135 of Neisseria meningitidis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DP has received travel grants from GlaxoSmithKline Vaccines to attend scientific meetings. AJP acts as chief investigator for clinical trials conducted on behalf of Oxford University and sponsored by vaccine manufacturers (Sanofi Pasteur MSD, Novartis Vaccines, GlaxoSmithKline Biologicals, Sanofi Pasteur and Wyeth Vaccines), and has directed trials of MenACYW vaccines, manufactured by Novartis Vaccines, and a Hib‐MenC vaccine, manufactured by GlaxoSmithKline Vaccines. He has received assistance from vaccine manufacturers to attend scientific meetings. Industry‐sourced consultancies and honoraria for lecturing or writing are paid directly to an independent charity or a fund held by the Department of Paediatrics, University of Oxford. He is an inventor on patents in the area of MenB vaccines.

References

    1. Pollard A J, Levin M. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 200019(4)333–344. - PubMed
    1. Martin D, Lopez L, McDowell R. The epidemiology of meningococcal disease in New Zealand in 2004. Report prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited (ESR). Wellington: Ministry of Health, 2005, Available from http://www.moh.govt.nz/publicationsbytitle (accessed 8 April 2007)
    1. Kirsch E A, Barton R P, Kitchen L.et al Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 199615(11)967–978. - PubMed
    1. Miller E, Salisbury D, Ramsay M E. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 200120(Suppl 1)S58–S67. - PubMed
    1. Snape M, Stone K, Pace D.et al Immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in infants. Abstract presented at the Meningitis Research Foundation's international conference: Meningitis and Septicaemia in Children and Adults, Burden of Illness, Management and Prospects for Prevention 2005, London, UK

MeSH terms

Substances